Ascletis Reports the Dosing of Four Healthy Patients of ASC11 in Multiple-Dose Escalation P-I Trial for COVID-19
Shots:
- The 4 patients have been dosed in the 1st cohort of the P-I multiple-dose escalation trial evaluating the safety, tolerability & PK of ASC11 (3-chymotrypsin-like protease inhibitor) + ritonavir (100mg). Study plans to enroll ~72 healthy patients (incl. 60 in single & multiple-dose escalation cohorts & 12 in food effect trial) with an expected completion in Q1’23
- ASC11 showed higher potency against SARS-CoV-2 over other 3CLpro inhibitors in antiviral cellular assays with inf. SARS-CoV-2 & remains potent antiviral activity against Omicron variants i.e., BA.1 and BA.5. The therapy also showed potent antiviral activity in the animal model
- Ascletis has submitted global patent applications for use of ASC11 & related compounds in viral disease
Ref: PRNewswire | Image: Ascletis
Related News:- Ascletis Receives the US FDA’s IND Approval of ASC11 for the Treatment of COVID-19
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
